Home
 |
RegeneRx Pipeline
RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.
RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.
June 2, 2020 Advisory: Update on ARISE-3 Dry Eye Trial
May 27, 2020 Advisory: Reclassification of Thymosin Beta 4 from New Drug Entity to Biologic
April 20, 2020 Advisory: Update on ARISE-3 Dry Eye Trial
March 18, 2020 Advisory: Update on Phase 3 Dry Eye Trial Amid COVID-19 Virus